Myelofibrosis physical examination: Difference between revisions
Jump to navigation
Jump to search
| Line 9: | Line 9: | ||
===Appearance of the Patient=== | ===Appearance of the Patient=== | ||
*Patients with myelofibrosis usually appear anemic. | *Patients with myelofibrosis usually appear anemic. | ||
===Vital Signs=== | |||
*High to low grade fever<ref name="pmid26123310">{{cite journal |vauthors=Shinar Y, Tohami T, Livneh A, Schiby G, Hirshberg A, Nagar M, Goldstein I, Cohen R, Kukuy O, Shubman O, Sharabi Y, Gonzalez-Roca E, Arostegui JI, Rechavi G, Amariglio N, Salomon O |title=Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis |journal=Orphanet J Rare Dis |volume=10 |issue= |pages=86 |date=June 2015 |pmid=26123310 |pmc=4506767 |doi=10.1186/s13023-015-0298-6 |url=}}</ref><ref name="pmid24403262">{{cite journal |vauthors=Mitra D, Kaye JA, Piecoro LT, Brown J, Reith K, Mughal TI, Sarlis NJ |title=Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review |journal=Cancer Med |volume=2 |issue=6 |pages=889–98 |date=December 2013 |pmid=24403262 |pmc=3892393 |doi=10.1002/cam4.136 |url=}}</ref><ref name="pmid23684482">{{cite journal |vauthors=Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S |title=Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study |journal=Leuk. Res. |volume=37 |issue=8 |pages=911–6 |date=August 2013 |pmid=23684482 |doi=10.1016/j.leukres.2013.04.017 |url=}}</ref> | |||
*Tachypnea and tachycardia (if severely anemic) | |||
===Skin=== | |||
*Petechiae and ecchymoses<ref name="pmid30405096">{{cite journal |vauthors=Finazzi G, Vannucchi AM, Barbui T |title=Prefibrotic myelofibrosis: treatment algorithm 2018 |journal=Blood Cancer J |volume=8 |issue=11 |pages=104 |date=November 2018 |pmid=30405096 |pmc=6221891 |doi=10.1038/s41408-018-0142-z |url=}}</ref><ref name="pmid29898956">{{cite journal |vauthors=Hofmann I, Geer MJ, Vögtle T, Crispin A, Campagna DR, Barr A, Calicchio ML, Heising S, van Geffen JP, Kuijpers MJE, Heemskerk JWM, Eble JA, Schmitz-Abe K, Obeng EA, Douglas M, Freson K, Pondarré C, Favier R, Jarvis GE, Markianos K, Turro E, Ouwehand WH, Mazharian A, Fleming MD, Senis YA |title=Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice |journal=Blood |volume=132 |issue=13 |pages=1399–1412 |date=September 2018 |pmid=29898956 |doi=10.1182/blood-2017-08-802769 |url=}}</ref><ref name="pmid28808761">{{cite journal |vauthors=Kc D, Falchi L, Verstovsek S |title=The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review |journal=Ann. Hematol. |volume=96 |issue=10 |pages=1595–1604 |date=October 2017 |pmid=28808761 |pmc=5693670 |doi=10.1007/s00277-017-3099-2 |url=}}</ref><ref name=complmf1radio1>Complications of primary myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 10, 2016</ref> | |||
*Skin nodules<ref name="pmid18705835">{{cite journal |vauthors=Miyata T, Masuzawa M, Katsuoka K, Higashihara M |title=Cutaneous extramedullary hematopoiesis in a patient with idiopathic myelofibrosis |journal=J. Dermatol. |volume=35 |issue=7 |pages=456–61 |date=July 2008 |pmid=18705835 |doi=10.1111/j.1346-8138.2008.00502.x |url=}}</ref><ref name="pmid18394406">{{cite journal |vauthors=Corella F, Barnadas MA, Bordes R, Curell R, Espinosa I, Vergara C, Alomar A |title=[A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis] |language=Spanish; Castilian |journal=Actas Dermosifiliogr |volume=99 |issue=4 |pages=297–300 |date=May 2008 |pmid=18394406 |doi= |url=}}</ref><ref name="pmid10405485">{{cite journal |vauthors=Kwon KS, Lee JB, Jang HS, Chung TA, Oh CK |title=A case of cutaneous extramedullary hematopoiesis in myelofibrosis with a preponderance of eosinophilic precursor cells |journal=J. Dermatol. |volume=26 |issue=6 |pages=379–84 |date=June 1999 |pmid=10405485 |doi= |url=}}</ref><ref name="pmid7784946">{{cite journal |vauthors=Ruberto E, Espinola R, Brusco J, Bacchiocchi M, Zoppi J, Paz R |title=[Idiopathic myelofibrosis with extramedullary hematopoiesis foci in the skin and testicles. Report of a case] |language=Spanish; Castilian |journal=Sangre (Barc) |volume=40 |issue=2 |pages=157–60 |date=April 1995 |pmid=7784946 |doi= |url=}}</ref> | |||
*Pallor<ref>{{cite book | last = Hoffman | first = Ronald | title = Hematology : basic principles and practice | publisher = Elsevier | location = Philadelphia, PA | year = 2018 | isbn = 9780323357623 }}</ref> | |||
==References== | ==References== | ||
Revision as of 22:13, 3 December 2018
|
Myelofibrosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Myelofibrosis physical examination On the Web |
|
American Roentgen Ray Society Images of Myelofibrosis physical examination |
|
Risk calculators and risk factors for Myelofibrosis physical examination |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]
Overview
Patients with myelofibrosis usually appear anemic. Physical examination of patients with myelofibrosis is usually remarkable for splenomegaly, hepatomegaly, skin pallor, petechiae and ecchymoses, and lymphoadenopathy.
Physical examination
Appearance of the Patient
- Patients with myelofibrosis usually appear anemic.
Vital Signs
Skin
References
- ↑ Shinar Y, Tohami T, Livneh A, Schiby G, Hirshberg A, Nagar M, Goldstein I, Cohen R, Kukuy O, Shubman O, Sharabi Y, Gonzalez-Roca E, Arostegui JI, Rechavi G, Amariglio N, Salomon O (June 2015). "Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis". Orphanet J Rare Dis. 10: 86. doi:10.1186/s13023-015-0298-6. PMC 4506767. PMID 26123310.
- ↑ Mitra D, Kaye JA, Piecoro LT, Brown J, Reith K, Mughal TI, Sarlis NJ (December 2013). "Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review". Cancer Med. 2 (6): 889–98. doi:10.1002/cam4.136. PMC 3892393. PMID 24403262.
- ↑ Mesa RA, Shields A, Hare T, Erickson-Viitanen S, Sun W, Sarlis NJ, Sandor V, Levy RS, Verstovsek S (August 2013). "Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study". Leuk. Res. 37 (8): 911–6. doi:10.1016/j.leukres.2013.04.017. PMID 23684482.
- ↑ Finazzi G, Vannucchi AM, Barbui T (November 2018). "Prefibrotic myelofibrosis: treatment algorithm 2018". Blood Cancer J. 8 (11): 104. doi:10.1038/s41408-018-0142-z. PMC 6221891. PMID 30405096.
- ↑ Hofmann I, Geer MJ, Vögtle T, Crispin A, Campagna DR, Barr A, Calicchio ML, Heising S, van Geffen JP, Kuijpers M, Heemskerk J, Eble JA, Schmitz-Abe K, Obeng EA, Douglas M, Freson K, Pondarré C, Favier R, Jarvis GE, Markianos K, Turro E, Ouwehand WH, Mazharian A, Fleming MD, Senis YA (September 2018). "Congenital macrothrombocytopenia with focal myelofibrosis due to mutations in human G6b-B is rescued in humanized mice". Blood. 132 (13): 1399–1412. doi:10.1182/blood-2017-08-802769. PMID 29898956. Vancouver style error: initials (help)
- ↑ Kc D, Falchi L, Verstovsek S (October 2017). "The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review". Ann. Hematol. 96 (10): 1595–1604. doi:10.1007/s00277-017-3099-2. PMC 5693670. PMID 28808761.
- ↑ Complications of primary myelofibrosis. Dr Henry Knipe and Dr Yuranga Weerakkody et al. Radiopaedia 2016. http://radiopaedia.org/articles/myelofibrosis. Accessed on March 10, 2016
- ↑ Miyata T, Masuzawa M, Katsuoka K, Higashihara M (July 2008). "Cutaneous extramedullary hematopoiesis in a patient with idiopathic myelofibrosis". J. Dermatol. 35 (7): 456–61. doi:10.1111/j.1346-8138.2008.00502.x. PMID 18705835.
- ↑ Corella F, Barnadas MA, Bordes R, Curell R, Espinosa I, Vergara C, Alomar A (May 2008). "[A case of cutaneous extramedullary hematopoiesis associated with idiopathic myelofibrosis]". Actas Dermosifiliogr (in Spanish; Castilian). 99 (4): 297–300. PMID 18394406.
- ↑ Kwon KS, Lee JB, Jang HS, Chung TA, Oh CK (June 1999). "A case of cutaneous extramedullary hematopoiesis in myelofibrosis with a preponderance of eosinophilic precursor cells". J. Dermatol. 26 (6): 379–84. PMID 10405485.
- ↑ Ruberto E, Espinola R, Brusco J, Bacchiocchi M, Zoppi J, Paz R (April 1995). "[Idiopathic myelofibrosis with extramedullary hematopoiesis foci in the skin and testicles. Report of a case]". Sangre (Barc) (in Spanish; Castilian). 40 (2): 157–60. PMID 7784946.
- ↑ Hoffman, Ronald (2018). Hematology : basic principles and practice. Philadelphia, PA: Elsevier. ISBN 9780323357623.